Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
about
Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.Ultrasonic-enhanced gentamicin transport through colony biofilms of Pseudomonas aeruginosa and Escherichia coliLong term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infectionThe extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin.Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin.Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Biofilm-related infections in ophthalmology.Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?Nox2 modification of LDL is essential for optimal apolipoprotein B-mediated control of agr type III Staphylococcus aureus quorum-sensing.Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin.Modulation of biofilms of Pseudomonas aeruginosa by quinolones.Effect of laser generated shockwaves 1 on ex-vivo pigskin.Erythromycin and diffuse panbronchiolitisApolipoprotein B48, the Structural Component of Chylomicrons, Is Sufficient to Antagonize Staphylococcus aureus Quorum-Sensing.Synergistic effect of clinically used antibiotics and peptide antibiotics against Gram-positive and Gram-negative bacteria.Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence.Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.Azithromycin paradox in the treatment of cystic fibrosis airway disease.Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis.The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance?Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model.Antibiotic prophylaxis and the medically compromised patient.Antibiofilm agents: A new perspective for antimicrobial strategy.Aii810, a Novel Cold-Adapted N-Acylhomoserine Lactonase Discovered in a Metagenome, Can Strongly Attenuate Pseudomonas aeruginosa Virulence Factors and Biofilm FormationMRT letter: Spatial distribution of vancomycin-induced damage in Staphylococcus epidermidis biofilm: an electron microscopic study.Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.Biofilm-related disease.Collismycin C from the Micronesian Marine Bacterium Streptomyces sp. MC025 Inhibits Staphylococcus aureus Biofilm Formation.
P2860
Q30403958-F45D4554-EF72-4F45-9FF3-20022DE4E54CQ30501322-050D04A3-E542-475C-879D-95B5421E4123Q33605247-51CF4D57-EAFE-40D7-BE0A-86A8A0044589Q33711476-489A9793-B13B-4957-8597-D9E1AB87B6BBQ33979968-A294ABA0-143A-45DB-9916-9972A6D0E879Q33983140-BFC5C381-FED5-4F34-9D6D-121D40E0A7B2Q34058659-049E0926-DF27-4085-8539-BE6D9D232BDEQ34375192-D1514C0C-5EE1-4FD0-812F-2CB2A5933A54Q34608010-007F5A26-93BE-4778-ABEC-E1844671BB02Q34720396-C683AA7E-8236-4586-8E58-F54D248C8C0CQ35119587-ECF7EE67-8789-462F-900D-334A25999940Q35233279-6F47FFE1-4E7B-44D4-96F2-2F7AA2EF608FQ35563192-CAC9DC2E-5C7E-45B0-A31B-137FDAB4DE3EQ35622488-CD9060F6-286B-44DA-A473-7FEAFA4B55C5Q37231245-F8FC6EAF-8B3B-4B98-AB6F-3F1B8F32AA01Q37358382-AB03931B-ADC9-4282-9928-5470D4B891AEQ37543436-64F0B4B1-9E0F-4D27-889F-166E54A14BD7Q39172960-C6FA7EC6-4556-4642-AF97-67CF0410D7F0Q39474230-377867B3-D40E-4218-B897-D13E816631B5Q39835134-0696DFD9-50C7-4593-849E-65271B65F448Q40284837-904C5EEC-BE5B-423B-9C63-74307672E3B9Q40536868-05A85AC9-C615-46A4-89CF-91C1EA973070Q40882597-83F5249B-6EC5-4B77-8719-F3B42E1D13A7Q41754792-A5ED81E2-FC7E-412C-BB40-F6EF4BDAC8AEQ41993542-33EBCE71-4834-41FB-9C81-5B9FB49C4E18Q42654254-81080211-EF08-45CD-8A86-4AE85428D3F9Q43008032-85222EDA-0C93-4E41-9A5F-82BBA0C73AD4Q45186613-D87AAC7E-078A-4668-8E60-E51598A708BEQ47254860-3AEB61DE-6D80-4DEF-B7C5-E130EB8C511BQ47258469-51BF77ED-B358-4C05-9BA3-34BAD517677E
P2860
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
@en
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
@nl
type
label
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
@en
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
@nl
prefLabel
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
@en
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
@nl
P2093
P2860
P356
P1476
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
@en
P2093
P2860
P304
P356
10.1128/AAC.37.9.1749
P407
P577
1993-09-01T00:00:00Z